Terms: = Small Cell Lung Cancer AND EGFR, mENA, 1956, ENSG00000146648, P00533, ERBB1, ERBB AND Prognosis
1331 results:
1. [Non-small cell lung carcinoma with co-expression of TTF1 and p40: a clinicopathological analysis of six cases].
Liu HS; Zhang YJ; Huang B; Ge HY; Cai LB; Chen MM
Zhonghua Bing Li Xue Za Zhi; 2024 Nov; 53(11):1111-1116. PubMed ID: 39482048
[No Abstract] [Full Text] [Related]
2. Concurrent egfr mutation and SMARCA4 deficiency in non-small cell lung cancer: A case report and literature review.
Dai W; Li T; Li Y; Chen C; Zhang X; Zhou P; Qi B
Medicine (Baltimore); 2024 Oct; 103(41):e40081. PubMed ID: 39465834
[TBL] [Abstract] [Full Text] [Related]
3. [Clinical characteristics and prognostic factors of epidermal growth factor receptor-mutated non-small cell lung cancer transformed into small-cell lung cancer after treatment].
Zheng H; Zhao D; Gu M; Wang QH; Li CH; Li X; Li J; Che NY; Hu Y
Zhonghua Yi Xue Za Zhi; 2024 Oct; 104(40):3751-3756. PubMed ID: 39463369
[No Abstract] [Full Text] [Related]
4. Targeting
Liu H; Qin J; Qian X
Cancer Control; 2024; 31():10732748241292782. PubMed ID: 39417568
[TBL] [Abstract] [Full Text] [Related]
5. [Pulmonary sarcomatoid carcinoma:report of three cases].
Wang ZX; Wang YM; Shen YQ; Wu YM; Wang N; Ren XX; Zhang XL
Zhonghua Jie He He Hu Xi Za Zhi; 2024 Oct; 47(10):960-964. PubMed ID: 39406543
[TBL] [Abstract] [Full Text] [Related]
6. Risk of COVID-19 infection in patients with NSCLC receiving egfr-TKI targeted therapy during the first wave in China.
Huang P; Liao LM; Zhao JL; Luo C; Yi YL; Chen Y; Huang L
J Int Med Res; 2024 Oct; 52(10):3000605241281907. PubMed ID: 39387199
[TBL] [Abstract] [Full Text] [Related]
7. Strategies for exploring mechanisms of polydatin against NSCLC based on experimentally validated network pharmacology and prognostic prediction of lipid metabolism gene expression.
Fan Z; Shuai H
Int Immunopharmacol; 2024 Dec; 142(Pt B):113172. PubMed ID: 39298823
[TBL] [Abstract] [Full Text] [Related]
8. Assessing the Sensitivity of Nested PCR Followed by Direct Sequencing on Exosomal DNA for egfr Mutation Detection in NSCL.
Jahani MM; Mashayekhi P; Omrani MD; Khosravi A; Ali D; Azad Manjiri S; Zahraei M; Mabani M; Seifi S; Salimi B; Rostami P
Iran Biomed J; 2024 Jul; 28(4):208-15. PubMed ID: 39289877
[TBL] [Abstract] [Full Text] [Related]
9. Prognostic impact of nectin-like molecule-5 (CD155) expression in non-small cell lung cancer.
Xitlally PN; Alejandro AS; Norma HP; Mario OM; Enrique CP; Cesar CR; José LL; Pedro BB; Juan-Manuel HM; Oscar A
J Transl Med; 2024 Sep; 22(1):841. PubMed ID: 39267111
[TBL] [Abstract] [Full Text] [Related]
10. Potential therapeutic option for egfr-mutant small cell lung cancer transformation: a case report and literature review.
Li X; Luan X; Zhang M; Wang R; Guo J; Lv J; Qiu W; Zhao S
Front Immunol; 2024; 15():1439033. PubMed ID: 39234244
[TBL] [Abstract] [Full Text] [Related]
11. Tumor markers in non-small cell lung cancer spine metastasis: an assessment of prognosis and overall survival.
Foresi B; Shah A; Meade S; Krishnaney A
Eur Spine J; 2024 Nov; 33(11):4346-4352. PubMed ID: 39223432
[TBL] [Abstract] [Full Text] [Related]
12. Multimodal radiomics-based methods using deep learning for prediction of brain metastasis in non-small cell lung cancer with
Zhu Y; Cong S; Zhang Q; Huang Z; Yao X; Cheng Y; Liang D; Hu Z; Shao D
Biomed Phys Eng Express; 2024 Sep; 10(6):. PubMed ID: 39214122
[No Abstract] [Full Text] [Related]
13. [Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2024 edition)].
Oncology Society of Chinese Medical Association
Zhonghua Yi Xue Za Zhi; 2024 Sep; 104(34):3175-3213. PubMed ID: 39193605
[TBL] [Abstract] [Full Text] [Related]
14. Immune-inflammatory markers and clinical characteristics as predictors of the depth of response and prognosis of patients with PD-L1 ≥50% metastatic non-small cell lung cancer receiving first-line immunotherapy.
Zheng X; Zhou L; Shi H; An J; Xu W; Ding X; Hua Y; Shi W; Li X
Thorac Cancer; 2024 Oct; 15(28):2029-2037. PubMed ID: 39189250
[TBL] [Abstract] [Full Text] [Related]
15. Whole-Exome Sequencing and Experimental Validation Unveil the Roles of TMEM229A Q200del Mutation in lung Adenocarcinoma.
Liang YX; Xie YP; Yu HM; Zhu WJ; Yin CY; Dong ZH; Zhang XL
Clin Respir J; 2024 Aug; 18(8):e70006. PubMed ID: 39188060
[TBL] [Abstract] [Full Text] [Related]
16. Strong PD-L1 affect clinical outcomes in advanced NSCLC treated with third-generation egfr-TKIs.
Niu J; Jing X; Xu Q; Liu H; Tian Y; Yang Z; Zhu H; Sun Y
Future Oncol; 2024; 20(32):2481-2490. PubMed ID: 39155845
[TBL] [Abstract] [Full Text] [Related]
17. [Non-small cell lung cancer with Metachronous Mutations of egfr and ALK Genes:
A Case Report and Literature Review].
Kong X; Wang M; Tang Q; Sun M; Hu J
Zhongguo Fei Ai Za Zhi; 2024 Jul; 27(7):559-564. PubMed ID: 39147711
[TBL] [Abstract] [Full Text] [Related]
18. Mechanisms of resistance and correlation between pre-treatment co-alterations and p-prognosis to osimertinib in chemo-naïve advanced non-small cell lung cancer.
Tamiya A; Osuga M; Harada D; Isa SI; Taniguchi Y; Nakamura K; Mizumori Y; Shinohara T; Yanai H; Nakatomi K; Oki M; Mori M; Kuwako T; Yamazaki K; Tamura A; Ando M; Koh Y
Lung Cancer; 2024 Sep; 195():107917. PubMed ID: 39116552
[TBL] [Abstract] [Full Text] [Related]
19. Landscape of Concomitant Driver Alterations in Classical
Wang H; Lin L; Liang C; Pang J; Yin JC; Zhang J; Shao Y; Sun C; Guo R
JCO Precis Oncol; 2024 Aug; 8():e2300520. PubMed ID: 39102631
[TBL] [Abstract] [Full Text] [Related]
20. Construction of a nomogram model based on biomarkers for liver metastasis in non-small cell lung cancer.
Zhang T; Zhang Y; Ni Y; Jia X; Li Y; Mao Z; Jiang P; Fu X; Jiao M; Jiang L; Wang W; Guo H; Zan Y; Liu M
Thorac Cancer; 2024 Sep; 15(26):1897-1911. PubMed ID: 39098998
[TBL] [Abstract] [Full Text] [Related]
[Next]